Post event: Anything new for oncology?

Post event: Anything new for oncology?

Post event: Anything new for oncology?

Lately, Basel Biometric Section and EFSPI organized a webinar “Estimands addendum is final: Anything new for oncology?”. You can find the program, the slides, a recording of the entire event, and a document that answers questions that were raised in the chat during the event on the BBS webpage.

In addition to Hannes Buchner from Staburo GmbH (1:23:53 of recording) and Ingolf Griebsch from Boehringer Ingelheim (1:12:30), Kaspar Rufibach from Roche (0:20), who is a member of the BBS board, Anja Schiel from the Norwegian Medicines Agency (6:55), Renaud Capdeville from Novartis (40:40), Tina Nielsen from Roche (54:33) and Stefan Englert from AbbVie (1:46:58) gave exciting lectures, which can be viewed on the webpage.

The panel discussion in the end was held from all speakers plus Rob Hemmings from Consilium and Michael Wenger from Novartis.

With just short of 400 registered participants the event was a huge success!

Data analysis, clinical biostatistics and more.

Staburo @ Joint EFSPI / BBS Webinar: Estimands addendum is final: Anything new for oncology?

Staburo @ Joint EFSPI / BBS Webinar: Estimands addendum is final: Anything new for oncology?

Staburo @ Joint EFSPI / BBS Webinar: Estimands addendum is final: Anything new for oncology?

We are very proud that Staburo’s Managing Director Dr. Hannes Buchner will be a speaker and will talk about “Treatment switching: challenges, estimands, and estimators”.

All information on registration and agenda of the event can be found on the BBS website.

This event was planned as a full-day seminar on the Novartis campus, but due to the current situation, the event will be performed in a webinar format.

Background: After the publication of the final version of the ICH E9 addendum, the BBS jointly with EFSPI would
like to offer a full-day seminar on the broad topic of estimands in oncology drug development. The
event will feature talks from statisticians and clinicians in industry, regulatory agencies, and academia.
It is the explicit intention of the event to extend the estimand discussion to those who partner with
statisticians in drug development, i.e. clinicians, regulatory colleagues, etc. For this reason, many of
the talks in the program are shared between a statistician and a clinician.
The intention is to make this the first of a series of events dedicated to estimands for specific
therapeutic areas. We start with oncology and envisage further seminars on, e.g., neuroscience.

The organizing committee members are Evgeny Degtyarev, Kaspar Rufibach, Bibiana Blatna, MarieLaure Casadebaig, Lynda Grinsted, Lorenzo Guizzaro, Wolfgang Kothny, Giusi Moffa, Hans-Jochen Weber. The event is supported by the European special interest group “Estimands in oncology”, sponsored by PSI and EFSPI, which is also an ASA scientific working group:
http://www.oncoestimand.org.

Initially, this event was planned as a full-day seminar on the Novartis campus. Given the current COVID19 situation we turn this event into a series of webinars. If you’d like to attend please fill out the registration form. After registration you will receive a calendar invite with a webex link. Slides and recordings of some of the talks will be made available after the event on the BBS webpage, both pending speaker approval.
The webinar is free of charge.

Data analysis, clinical biostatistics and more.

How to Avoid Overfitting, Precision Medicine in Action & Tumour Growth Modelling – three PSI contributions

How to Avoid Overfitting, Precision Medicine in Action & Tumour Growth Modelling – three PSI contributions

 

Staburo’s 2020 PSI contributions in webinar format on 26 May (15:00 – 17:15 CET)

Since the 2020 PSI conference will unfortunately not take place, we decided to share our PSI contributions in an online live webinar with our colleagues. Staburo biostatisticians Nicole Krämer, Laura Schlieker and Hannes Buchner will talk about “How to Avoid Overfitting, Precision Medicine in Action & Tumour Growth Modelling” on 26 May (15:00 – 17:15 CET). You find the agenda and abstracts of the talks  below.

If you want to join the webinar please send us an email with your name to info@staburo.de or use the sign up button below. We will not use any of your personal information for other purposes than for giving you access to the online live presentations. Participation is free of charge. We are looking forward to this online event with you! 

Sign up now!

 

Abstract Nicole Krämer’s talk (approx. 15:00 – 15:45 CET on 26 May):

This presentation in based on joint work by Nicole Krämer, Carina Ittrich (Boehringer Ingelheim) and Josef Höfler (Staburo).

The identification of patient subgroups who derive benefit from a new treatment is of crucial importance in precision medicine. For a clinical trial that compares an experimental treatment E to a control treatment C using a time-to-event endpoint, this may translate to finding a subgroup in which the hazard ratio E versus C is particularly low.

Many subgroup identification algorithms have been proposed and studied. They range from cut-off optimization for single biomarkers to the virtual twin method or high-dimensional gene-expression signatures. In general, they differ in the underlying estimand and in the way the subgroup is identified. However, due to their data-driven nature, the estimated relative treatment benefit (e.g. the hazard ratio) within the identified subgroup is almost always biased. This in turn has considerable implications on the clinical development as these ‘naïve’ subgroup effects are too optimistic and cannot be reproduced in a new trial.

We propose cross-validation to obtain a more realistic subgroup effect. In each cross-validation split, the subgroup identification algorithm is applied to the training set. The obtained rule is used to assign patients in the test set to the subgroup or its complement. We define the cross-validated relative treatment benefit as the relative treatment benefit based on this subgroup assignment.

In extensive simulations, we show that on average, the cross-validated relative treatment benefit is very close to the true relative treatment benefit. The approach is further illustrated in an application to a breast cancer study.

 

Abstract  Laura Schlieker’s talk (approx. 15:45 – 16:30 CET on 26 May):

This presentation in based on joint work by Laura Schlieker, Nicole Krämer, Volker Heinemann (LMU Munich), Arndt Stahler (LMU Munich) and Sebastian Stintzing (LMU Munich).

The choice of the right treatment for patients based on their individual genetic profile is of utmost importance in precision medicine. To identify potential signals within the large number of biomarkers it is mandatory to define criteria for signal detection beforehand and apply appropriate statistical models in the setting of high dimensional data.

For the identification of predictive and prognostic genetic variants as well as tumor mutational burden (TMB) in patients with metastatic colorectal cancer, we derived the following pre-defined and hierarchical criteria for signal detection.

  1. All biomarkers identified via a multivariate variable selection procedure
  2. If a) reveals no signal, all biomarkers with adjusted p-value ≤ 0.157
  3. If neither a) nor b) reveals signals, the top 5 biomarkers according to sorted, adjusted p-value

Regularized regression models were used for variable selection, and the stability of the selection process was quantified and visualized. Selected biomarkers were analyzed in terms of their predictive potential on a continuous scale.

With our analyses we confirmed the predictive potential of several already known biomarkers and identified additional promising candidate variants. Furthermore, we identified TMB as a potential prognostic biomarker with a trend towards prolonged survival for patients with high TMB.

Our analyses were supported by power simulations for the variable selection method, assuming different prevalences of biomarkers, numbers of truly predictive biomarkers and effect sizes.

 

Abstract Hannes Buchner’s talk (approx. 16:30 – 17:15 CET on 26 May):

This presentation in based on joint work by Hannes Buchner and Gabriele Bleckert (Staburo).

In oncology, reliable estimates of progression-free-survival (PFS) are of highest importance because of high failure rates of phase III trials (around 60%). However, PFS-estimations on early readouts with less than 50% of events observed do not use all available information from tumour measurements over time.

We project the PFS-event of each censored patient by using a mixed model describing the tumour burden over time. RECIST-criteria are applied on estimated patient-specific non-linear tumour-trajectories to calculate the projected time-to-progression. PFS is compared between test and reference by hazard ratios.

Several phase III and II simulations with 1000 runs each with 2000 or 80 patients, 6 months accrual and 2 (scenario-1) or 6 months (scenario-2) follow-up were performed. All simulations are based on a published optimal parameterisation of tumour-growth in NSCLC which implies a time-dependent HR.

 

Sign up now!

Data analysis, clinical biostatistics and more.

Staburo supported evaluation of medical device which got FDA Emergency Use Authorization for COVID-19

Staburo supported evaluation of medical device which got FDA Emergency Use Authorization for COVID-19

Staburo supported evaluation of medical device which recently got FDA Emergency Use Authorization for COVID-19

Staburo Managing Director Dr. Hannes Buchner and our team was involved in statistical consulting and performing data analysis in a trial for a medical device which is now being used in COVID-19 patients.

The device binds SARS-CoV-2 and removes it from the blood. It has been shown to also remove inflammatory markers such as IL-6. Other inflammatory markers that have correlated to poor outcome such as d-dimers and Ferritin have decreased during and after treatment. Stabilization of blood pressure has also been reported and reduction in the need for vasopressors. This allows additional time for supportive care while reducing the source of inflammation and preventing further damage caused by the pathogen.

Further information can be found on the company’s website: www.extheramedical.com

 

Data analysis, clinical biostatistics and more.

Staburo team home office workout

Staburo team home office workout

Staburo team stays healthy, positive and at home

The Staburo team is entirely working from home, which works quite seamlessly thanks to a well prepared IT infrastructure and software tools.

To keep a positive attitude during uncertain times, Staburo Managing Director Roland Stieger decided to offer short morning workouts via MS Teams to start the home office day fresh, until the situation (especially in our neighboring countries) hopefully eases.

We are very proud to support the pharmaceutical industry with our services, which is the only industry that can build sustainable weapons against infectious diseases.

Data analysis, clinical biostatistics and more.

Students from the University of Copenhagen visited Staburo

Students from the University of Copenhagen visited Staburo

Students from the University of Copenhagen visited Staburo

Nine Master students from the University of Copenhagen visited Staburo as part of their Statistical Study Trip to Munich.

After a welcome from our Managing Director Josef Höfler, the students learned more about how statistics is applied in the “real world”. Many topics were covered, including biostatistics, programming, consulting and precision medicine. After an office tour and a short overview on potential Master and PhD theses, the students discussed with our employees about what it is like to work as a statistician in a company.

We had a great time presenting the various exciting areas of work at Staburo. If you are also interested in our expertise, do not hesitate to contact us.

Data analysis, clinical biostatistics and more.